CN113214070B - Preparation method of aurantio-obtusin and application of aurantio-obtusin in health-care product for relaxing bowels - Google Patents
Preparation method of aurantio-obtusin and application of aurantio-obtusin in health-care product for relaxing bowels Download PDFInfo
- Publication number
- CN113214070B CN113214070B CN202110521022.2A CN202110521022A CN113214070B CN 113214070 B CN113214070 B CN 113214070B CN 202110521022 A CN202110521022 A CN 202110521022A CN 113214070 B CN113214070 B CN 113214070B
- Authority
- CN
- China
- Prior art keywords
- obtusin
- aurantio
- parts
- preparation
- health
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- RNXZPKOEJUFJON-UHFFFAOYSA-N aurantio-obtusin Chemical compound CC1=C(O)C(OC)=C2C(=O)C3=C(O)C(OC)=C(O)C=C3C(=O)C2=C1 RNXZPKOEJUFJON-UHFFFAOYSA-N 0.000 title claims abstract description 110
- 238000002360 preparation method Methods 0.000 title claims abstract description 37
- 230000002040 relaxant effect Effects 0.000 title claims abstract description 13
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 40
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 40
- 239000000243 solution Substances 0.000 claims abstract description 28
- 238000002156 mixing Methods 0.000 claims abstract description 22
- 239000000843 powder Substances 0.000 claims abstract description 21
- 239000008141 laxative Substances 0.000 claims abstract description 20
- 230000002475 laxative effect Effects 0.000 claims abstract description 20
- 239000002904 solvent Substances 0.000 claims abstract description 18
- 239000003480 eluent Substances 0.000 claims abstract description 16
- 238000010992 reflux Methods 0.000 claims abstract description 14
- 229940076742 senna leaves Drugs 0.000 claims abstract description 14
- 239000007788 liquid Substances 0.000 claims abstract description 13
- 235000002722 Dioscorea batatas Nutrition 0.000 claims abstract description 11
- 235000006536 Dioscorea esculenta Nutrition 0.000 claims abstract description 11
- 240000001811 Dioscorea oppositifolia Species 0.000 claims abstract description 11
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 claims abstract description 11
- 244000197580 Poria cocos Species 0.000 claims abstract description 11
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 11
- 238000010438 heat treatment Methods 0.000 claims abstract description 9
- 239000011259 mixed solution Substances 0.000 claims abstract description 8
- 238000001816 cooling Methods 0.000 claims abstract description 7
- 238000001914 filtration Methods 0.000 claims abstract description 6
- 238000010898 silica gel chromatography Methods 0.000 claims abstract description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 18
- 244000269722 Thea sinensis Species 0.000 claims description 18
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 14
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 14
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical group O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 11
- 239000002245 particle Substances 0.000 claims description 11
- 230000036541 health Effects 0.000 claims description 10
- 235000006468 Thea sinensis Nutrition 0.000 claims description 9
- 235000020279 black tea Nutrition 0.000 claims description 9
- 235000009569 green tea Nutrition 0.000 claims description 9
- 235000012907 honey Nutrition 0.000 claims description 9
- 239000003208 petroleum Substances 0.000 claims description 8
- 210000000582 semen Anatomy 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 4
- 230000000694 effects Effects 0.000 abstract description 9
- 244000201986 Cassia tora Species 0.000 abstract description 5
- 235000014552 Cassia tora Nutrition 0.000 abstract description 5
- 238000013329 compounding Methods 0.000 abstract description 3
- 239000000047 product Substances 0.000 description 29
- 230000013872 defecation Effects 0.000 description 17
- 238000000605 extraction Methods 0.000 description 16
- 230000000052 comparative effect Effects 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 239000011812 mixed powder Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- LQGUBLBATBMXHT-UHFFFAOYSA-N chrysophanol Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000013642 negative control Substances 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- -1 rhein Chemical compound 0.000 description 4
- 238000007873 sieving Methods 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 206010010774 Constipation Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- NZPQWZZXRKZCDU-UHFFFAOYSA-N chrysophanol Natural products Cc1cc(O)c2C(=O)c3c(O)cccc3Oc2c1 NZPQWZZXRKZCDU-UHFFFAOYSA-N 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 description 2
- 239000010282 Emodin Substances 0.000 description 2
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 description 2
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 2
- 150000004056 anthraquinones Chemical class 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 229960004192 diphenoxylate Drugs 0.000 description 2
- 238000007599 discharging Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 2
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 238000002386 leaching Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- QZMAEZWZCGBZFK-AOJWCAIYSA-N (2s,3s,4s,5r,6r)-6-[[(3s,4ar,6ar,6bs,8as,12as,14ar,14br)-4,4,6a,6b,11,11,14b-heptamethyl-8a-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxycarbonyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-3,5-dihydroxy-4-[(2s,3r Chemical compound O([C@H]1[C@H](O)[C@H](O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@]1(CCC(C[C@H]14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C(O)=O)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O QZMAEZWZCGBZFK-AOJWCAIYSA-N 0.000 description 1
- QZMAEZWZCGBZFK-UHFFFAOYSA-N 28-(beta-D-Glucopyranosyloxy)-28-oxoolean-12-en-3beta-yl 3-O-(beta-D-glucopyranosyl)-beta-D-glucopyranosiduronic acid Natural products C12CC(C)(C)CCC2(C(=O)OC2C(C(O)C(O)C(CO)O2)O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC(C1O)OC(C(O)=O)C(O)C1OC1OC(CO)C(O)C(O)C1O QZMAEZWZCGBZFK-UHFFFAOYSA-N 0.000 description 1
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 1
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 1
- 206010002153 Anal fissure Diseases 0.000 description 1
- 208000016583 Anus disease Diseases 0.000 description 1
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 244000277285 Cassia obtusifolia Species 0.000 description 1
- 235000006719 Cassia obtusifolia Nutrition 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010016100 Faeces discoloured Diseases 0.000 description 1
- 208000009531 Fissure in Ano Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 240000003394 Malpighia glabra Species 0.000 description 1
- 235000014837 Malpighia glabra Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- CFLNHFUPWNRWJA-UHFFFAOYSA-N Obtusin Chemical compound O=C1C2=CC(C)=C(O)C(OC)=C2C(=O)C2=C1C=C(OC)C(OC)=C2O CFLNHFUPWNRWJA-UHFFFAOYSA-N 0.000 description 1
- OBBJQZSMXOJMCN-UHFFFAOYSA-N Obtusin Natural products COc1cc2C=CC(=O)Oc2c3OCC(Oc13)C(=C)C OBBJQZSMXOJMCN-UHFFFAOYSA-N 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 1
- 206010038084 Rectocele Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 208000027503 bloody stool Diseases 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- HWJHWSBFPPPIPD-UHFFFAOYSA-N ethoxyethane;propan-2-one Chemical compound CC(C)=O.CCOCC HWJHWSBFPPPIPD-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- KPJWZUAARPJYSB-UHFFFAOYSA-N glycoside C Natural products CC1(C)OC(=O)C23CCC1C2(O)CCC(C1(CCC24)C)(C)C3CCC1C2(C)CCCC4(C)COC(C(C(O)C1O)OC2C(C(O)C(CO)O2)O)OC1COC1OC(CO)C(O)C(O)C1O KPJWZUAARPJYSB-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- NIQQIJXGUZVEBB-UHFFFAOYSA-N methanol;propan-2-one Chemical compound OC.CC(C)=O NIQQIJXGUZVEBB-UHFFFAOYSA-N 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- QYPPHFQJBYFVJC-KWFWBHSNSA-M sodium;[(3s,5s,6s,8s,10s,13s,14s,17s)-6-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r)-5-[(2s,3r,4s,5r,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-4-hydroxy-3-[(2r,3s,4r,5r,6s)-3,4,5-trihydroxy-6-methylo Chemical compound [Na+].O([C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1CO[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@H]([C@H](O)[C@@H](O)[C@H](C)O1)O)O[C@H]1[C@H](O)[C@@H](C)O[C@H]([C@@H]1O)O[C@H]1C[C@H]2[C@@H]3CC[C@@H]([C@]3(CC=C2[C@@]2(C)CC[C@@H](C[C@@H]21)OS([O-])(=O)=O)C)[C@](C)(O)CC(=O)CC(C)C)[C@@H]1O[C@H](C)[C@@H](O)[C@H](O)[C@H]1O QYPPHFQJBYFVJC-KWFWBHSNSA-M 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C50/00—Quinones
- C07C50/26—Quinones containing groups having oxygen atoms singly bound to carbon atoms
- C07C50/34—Quinones containing groups having oxygen atoms singly bound to carbon atoms the quinoid structure being part of a condensed ring system having three rings
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
- A61K35/644—Beeswax; Propolis; Royal jelly; Honey
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C46/00—Preparation of quinones
- C07C46/10—Separation; Purification; Stabilisation; Use of additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
- C07C2603/22—Ortho- or ortho- and peri-condensed systems containing three rings containing only six-membered rings
- C07C2603/24—Anthracenes; Hydrogenated anthracenes
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Insects & Arthropods (AREA)
- Animal Husbandry (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a preparation method of aurantio-obtusin and application of the aurantio-obtusin in a health-care product for relaxing bowels, wherein the preparation method of the aurantio-obtusin comprises the following steps: (1) mixing the coarse powder of the cassia seeds with a solvent, and performing microwave-assisted treatment to obtain a pretreatment solution; (2) heating, refluxing, cooling and filtering the pretreatment liquid obtained in the step (1) to obtain a mixed liquid; (3) carrying out silica gel column chromatography on the mixed solution obtained in the step (2), eluting, and collecting eluent; (4) and (4) concentrating the eluent obtained in the step (3), and recrystallizing to obtain the aurantio-obtusin. The preparation method of the invention obviously improves the yield and purity of the aurantio-obtusin. Compared with the prior art, the laxative health-care product disclosed by the invention has the advantages that the consumption of the senna leaves and the cassia seeds is obviously reduced by compounding the orange cassia tora essence with the senna leaves, the poria cocos, the radix glehniae, the Chinese yam and the like, the effect of relaxing bowel is obvious, and the safety is higher.
Description
Technical Field
The invention belongs to the technical field of extraction of active ingredients of traditional Chinese medicines, and particularly relates to a preparation method of aurantio-obtusin and application of the aurantio-obtusin in a health-care product for relaxing bowels.
Background
Cassia seed, originally recorded in Shennong Ben Cao Jing, is a dry mature seed of Cassia obtusifolia Cass ia Obtus ifolia L. or Cassia tora siata a L. of leguminous plants, and has cold, sweet and bitter taste, and enters liver and large intestine meridians. Modern pharmacological research shows that cassia seed has pharmacological activities of reducing blood pressure, reducing blood fat, inhibiting bacteria, relieving asthma, benefiting gallbladder, protecting liver, resisting oxidation, resisting atherosclerosis, enhancing immunity and the like. It contains anthraquinones such as chrysophanol, emodin, rhein, aurantio-obtusin, and obtusin.
The aurantio-obtusin is a yellow acerola anthraquinone compound, is a special component in cassia seed, and has the effects of reducing blood fat, estrogen and antiestrogen activity, reducing blood sugar, and inducing platelet aggregation by adenosine diphosphate (A DP), Arachidonic Acid (AA), collagen (co lla-gen), and the like.
At present, most researches on the extraction process of the cassia seeds take emodin and chrysophanol as indexes, and reports taking the content of orange cassia tora element as an index are hardly seen.
CN111228325A discloses a method for extracting the whole components of cassia seed by fusing supercritical CO2The extraction technology and the high-pressure-difference low-temperature continuous extraction technology adopt two extraction modes, all effective components in the cassia seeds are respectively extracted and converted into finished products to the greatest extent, the added value of the products is improved, the use amount of organic solvents is reduced, meanwhile, the high extraction rate of various effective components is ensured, the pollution is reduced, and the extraction rates of total flavonoids, polysaccharides, chrysophanol, aurantiamarin, cassia seed glycoside C and cassia seed glycoside B2 are all up to more than 65%. However, the extraction method of the present invention uses expensive equipment and has high preparation cost.
CN101967090A discloses an extraction process of aurantio-obtusin, which comprises the steps of crushing cleaned cassia seeds into coarse powder, leaching in solvent gasoline, discarding the leaching solution, adding residues into an alcohol solvent for ultrasonic extraction, concentrating the extracting solution, performing Soxhlet reflux extraction by using ethyl acetate, concentrating the ethyl acetate extracting solution, passing the ethyl acetate extracting solution through a polyamide chromatographic column, eluting by using petroleum ether-acetone and acetone-methanol, recovering the solvent from the eluent at low temperature under reduced pressure to obtain a crude product, and recrystallizing the crude product by using N-dimethylformamide/acetone to obtain the aurantio-obtusin. The method has simple extraction equipment, the purity of the obtained aurantio-obtusin is between 98.27 and 98.62 percent, but the method has low yield, long extraction time and great harm to the environment and human bodies, and is not suitable for industrial production.
Zhang Jing reports mixing semen Cassiae powder with 15% sulfuric acid solution, heating in water bath, separating hydrolyzed substances with filter paper and a funnel, distilling with distilled water to obtain anthraquinone aglycone solution, heating and refluxing at 70 ℃ with ethanol, cooling, correcting lost weight with ethanol, separating the mixed solution with a silica gel chromatographic column, collecting the liquid passing through the chromatographic column into a conical flask, eluting with eluent of petroleum ether and acetone at a ratio of 9:1 to obtain aurantio-obtusin, and recrystallizing the separated aurantio-obtusin for many times with an evaporating dish and acetone to obtain aurantio-obtusin with a purity of 99% (research and analysis on separation and extraction of the aurantio-obtusin, China and foreign medicine research, volume 10, and 20 th period). The invention provides a technology for obtaining high-purity aurantio-obtusin to a certain extent, but still has the problem that the yield and the purity of aurantio-obtusin can not be improved simultaneously.
The modern society has fast pace of life and high working pressure, and a lot of people are in sub-health state. The sub-healthy people are most susceptible to gastrointestinal discomfort, constipation, obesity, insomnia, hypertension, hyperlipidemia, cerebrovascular diseases and hypoimmunity. Constipation is a complex symptom common in the clinic and usually manifests as: less defecation and less defecation times; difficult and laborious defecation; the defecation is not smooth; dry stool, hard stool and unclean defecation. The long-term constipation can be accompanied by symptoms of abdominal distension, abdominal pain, bloody stool and the like, and easily induces the attack of cardiovascular and cerebrovascular diseases and serious hemorrhoids, anal fissure, rectocele and other diseases.
In recent years, with the more and more obvious pharmacological action and physiological activity of aurantio-obtusin, the more and more effect of aurantio-obtusin on the aspect of preventing and treating diseases by traditional Chinese medicines is achieved, so that the development of a preparation method of aurantio-obtusin capable of solving the technical problems and the application of aurantio-obtusin in health products for relaxing bowels are very necessary.
Disclosure of Invention
In order to solve the problems, the invention provides a preparation method of the aurantio-obtusin, which has high yield and purity, simple preparation process and low cost, and application of the aurantio-obtusin prepared by the preparation method in health-care products for relaxing bowels.
In order to achieve the purpose, the invention adopts the following technical scheme:
a preparation method of aurantio-obtusin comprises the following steps:
(1) mixing the coarse powder of the cassia seeds with a solvent, and performing microwave-assisted treatment to obtain a pretreatment solution;
(2) heating, refluxing, cooling and filtering the pretreatment liquid obtained in the step (1) to obtain a mixed liquid;
(3) carrying out silica gel column chromatography on the mixed solution obtained in the step (2), eluting, and collecting eluent;
(4) and (4) concentrating the eluent obtained in the step (3), and recrystallizing to obtain the aurantio-obtusin.
Preferably, the particle size of the cassia seed coarse powder in the step (1) is 0.05-0.25 mm.
Preferably, the solvent in the step (1) is ethanol water solution and n-butanol in a volume ratio of 8-10: 1.
Further preferably, the volume concentration of the ethanol water solution is 50-70%.
Preferably, the mass ratio of the cassia seed coarse powder to the solvent in the step (1) is 1: 10-15.
Preferably, the microwave-assisted treatment in step (1) is: the microwave power is 300-400W, and the microwave time is 20-40 s.
Preferably, the heating reflux in step (2) is: reflux extracting at 60-70 deg.C for 15-30 min.
Preferably, the eluent in the step (2) is a mixed solution of petroleum ether and acetone.
Further preferably, the mass ratio of the petroleum ether to the acetone is 6.5:1-8.5: 1.
The invention also provides the orange cassia seed element prepared by the preparation method.
The invention also provides application of the aurantio-obtusin prepared by the preparation method in preparation of health-care products for relaxing bowels.
The invention also provides a health-care product for relaxing bowels, which comprises the orange cassia essence prepared by the preparation method.
Preferably, the laxative health-care product comprises 10-15 parts of senna leaves, 8-15 parts of cassia seeds, 5-15 parts of black tea, 5-15 parts of green tea, 3-12 parts of poria cocos, 3-12 parts of radix glehniae, 20-30 parts of Chinese yam and 5-10 parts of honey.
The preparation method of the laxative health-care product comprises the following steps:
s1, respectively pulverizing folium sennae, black tea, green tea, Poria, radix Glehniae and rhizoma Dioscoreae, sieving with 10-30 mesh sieve, and mixing to obtain mixed powder;
s2, pretreating semen cassiae according to the preparation method to obtain aurantio-obtusin;
s3, mixing the aurantio-obtusin obtained in the step S2 with honey, adding the mixed powder obtained in the step S1, and uniformly mixing to obtain a wet material;
s4, performing irradiation sterilization on the wet material obtained in the step S3, and granulating to obtain the laxative health-care product.
Compared with the prior art, the invention has the beneficial effects that:
(1) the invention carries out auxiliary treatment on the alcohol solution of the cassia seed coarse powder by microwave, then carries out heating reflux, utilizes silica gel column and recrystallization to separate and purify the aurantio-obtusin, and obviously improves the yield and the purity of the aurantio-obtusin by optimizing the parameters of the particle size of the cassia seed coarse powder, the concentration and the dosage of the alcohol solution, the microwave condition, the composition of an eluant and the like.
(2) The preparation method is simple, has low requirements on equipment, short preparation time and low production cost, and simultaneously has less reagent dosage and is beneficial to environmental protection.
(3) Compared with the prior art, the laxative health-care product disclosed by the invention has the advantages that the consumption of the senna leaves and the cassia seeds is obviously reduced by compounding the orange cassia tora essence with the senna leaves, the poria cocos, the radix glehniae, the Chinese yam and the like, the effect of relaxing bowel is obvious, and the safety is higher.
Detailed Description
The embodiments of the present invention are described below with reference to specific embodiments, and other advantages and effects of the present invention will be easily understood by those skilled in the art from the disclosure of the present specification. The invention is capable of other and different embodiments and of being practiced or of being carried out in various ways, and its several details are capable of modification in various respects, all without departing from the spirit and scope of the present invention.
Before the present embodiments are further described, it is to be understood that the scope of the invention is not limited to the particular embodiments described below; it is also to be understood that the terminology used in the examples is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention.
When numerical ranges are given in the examples, it is understood that both endpoints of each of the numerical ranges and any value therebetween can be selected unless the invention otherwise indicated. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
Unless otherwise stated, the raw materials used in the present invention are all common commercial products, the diameter-height ratio of the chromatography column in this example is 1:5, and the silica gel is 300 mesh.
Example 1
A preparation method of aurantio-obtusin comprises the following steps:
(1) mixing the components in a mass ratio of 1: 10, mixing the coarse powder of the cassia seeds with a solvent, and performing microwave-assisted treatment to obtain a pretreatment solution;
wherein the particle size of the cassia seed coarse powder is 0.05 mm;
the solvent is ethanol water solution and n-butanol with the volume ratio of 8:1, and the volume concentration of the ethanol water solution is 70%;
the microwave-assisted treatment comprises the following steps: the microwave power is 300W, and the microwave time is 40 s;
(2) carrying out reflux extraction on the pretreatment liquid obtained in the step (1) at 60 ℃ for 30min, cooling and filtering to obtain a mixed liquid;
(3) performing silica gel column chromatography on the mixed solution obtained in the step (2), eluting with petroleum ether and acetone in a mass ratio of 6.5:1, and collecting eluent;
(4) and (4) concentrating the eluent obtained in the step (3), and recrystallizing to obtain the aurantio-obtusin.
A laxative health product comprises the following components in parts by weight: 10 parts of senna leaves, 15 parts of cassia seeds, 5 parts of black tea, 5 parts of green tea, 3 parts of poria cocos, 3 parts of radix glehniae, 20 parts of Chinese yam and 5 parts of honey;
the preparation method of the laxative health-care product comprises the following steps:
s1, respectively crushing the senna leaves, the black tea, the green tea, the poria cocos, the radix glehniae and the Chinese yam according to the formula amount, sieving by a 10-mesh sieve, and mixing to obtain mixed powder;
s2, pretreating the cassia seeds according to the formula amount according to the preparation method of the embodiment 1 to obtain the aurantio-obtusin;
s3, mixing the aurantio-obtusin obtained in the step S2 with honey, adding the mixed powder obtained in the step S1, and uniformly mixing to obtain a wet material;
s4, performing irradiation sterilization on the wet material obtained in the step S3, and granulating to obtain the laxative health-care product.
Example 2
A preparation method of aurantio-obtusin comprises the following steps:
(1) mixing the components in a mass ratio of 1: 15, mixing the coarse powder of the cassia seeds with a solvent, and performing microwave-assisted treatment to obtain a pretreatment solution;
wherein the particle size of the cassia seed coarse powder is 0.25 mm;
the solvent is ethanol water solution and n-butanol with the volume ratio of 10:1, and the volume concentration of the ethanol water solution is 50%;
the microwave-assisted treatment comprises the following steps: the microwave power is 400W, and the microwave time is 20 s;
(2) carrying out reflux extraction on the pretreatment liquid obtained in the step (1) at 70 ℃ for 15min, cooling and filtering to obtain a mixed liquid;
(3) performing silica gel column chromatography on the mixed solution obtained in the step (2), eluting with petroleum ether and acetone in a mass ratio of 8.5:1, and collecting eluent;
(4) and (4) concentrating the eluent obtained in the step (3), and recrystallizing to obtain the aurantio-obtusin.
A laxative health product comprises the following components in parts by weight: 15 parts of senna leaves, 8 parts of cassia seeds, 15 parts of black tea, 15 parts of green tea, 12 parts of poria cocos, 12 parts of radix glehniae, 20 parts of Chinese yam and 10 parts of honey;
the preparation method of the laxative health-care product comprises the following steps:
s1, respectively crushing the senna leaves, the black tea, the green tea, the poria cocos, the radix glehniae and the Chinese yam according to the formula amount, sieving by a 30-mesh sieve, and mixing to obtain mixed powder;
s2, pretreating the cassia seeds according to the formula amount according to the preparation method of the embodiment 1 to obtain the aurantio-obtusin;
s3, mixing the aurantio-obtusin obtained in the step S2 with honey, adding the mixed powder obtained in the step S1, and uniformly mixing to obtain a wet material;
s4, performing irradiation sterilization on the wet material obtained in the step S3, and granulating to obtain the laxative health-care product.
Example 3
A preparation method of aurantio-obtusin comprises the following steps:
(1) mixing the components in a mass ratio of 1: 12, mixing the coarse powder of the cassia seeds with a solvent, and performing microwave-assisted treatment to obtain a pretreatment solution;
wherein the particle size of the cassia seed coarse powder is 0.15 mm;
the solvent is ethanol water solution and n-butanol with the volume ratio of 9:1, and the volume concentration of the ethanol water solution is 60%;
the microwave-assisted treatment comprises the following steps: the microwave power is 338W, and the microwave time is 30 s;
(2) carrying out reflux extraction on the pretreatment liquid obtained in the step (1) at 65 ℃ for 20min, cooling and filtering to obtain a mixed liquid;
(3) performing silica gel column chromatography on the mixed solution obtained in the step (2), eluting with petroleum ether and acetone in a mass ratio of 7:1, and collecting eluent;
(4) and (4) concentrating the eluent obtained in the step (3), and recrystallizing to obtain the aurantio-obtusin.
A laxative health product comprises the following components in parts by weight: 12 parts of senna leaves, 12 parts of cassia seeds, 10 parts of black tea, 10 parts of green tea, 8 parts of poria cocos, 5 parts of radix glehniae, 25 parts of Chinese yam and 8 parts of honey;
the preparation method of the laxative health-care product comprises the following steps:
s1, respectively crushing the senna leaves, the black tea, the green tea, the poria cocos, the radix glehniae and the Chinese yam according to the formula amount, sieving by a 20-mesh sieve, and mixing to obtain mixed powder;
s2, pretreating the cassia seeds according to the formula amount according to the preparation method of the embodiment 1 to obtain the aurantio-obtusin;
s3, mixing the aurantio-obtusin obtained in the step S2 with honey, adding the mixed powder obtained in the step S1, and uniformly mixing to obtain a wet material;
s4, performing irradiation sterilization on the wet material obtained in the step S3, and granulating to obtain the laxative health-care product.
Comparative example 1
The difference between the comparative example and the example 3 is that in the preparation method of the aurantio-obtusin, the particle size of the semen cassiae coarse powder is 0.3 mm;
the solvent is ethanol water solution and n-butanol with the volume ratio of 15: 1;
the power of the microwave-assisted treatment is 500W, and the microwave time is 15 s.
Comparative example 2
The difference between the comparative example and the example 3 is that in the preparation method of the aurantio-obtusin, the particle size of the semen cassiae coarse powder is 0.01 mm;
the solvent is ethanol water solution and n-butanol with the volume ratio of 5: 1;
the power of the microwave auxiliary treatment is 250W, and the microwave time is 50 s.
Comparative example 3
CN107361173A a laxative health product prepared in example 3.
Experimental example I evaluation of physical and chemical indexes of orange-yellow cassia seed extract
Examples 1-3 and comparative examples 1-2 were prepared to obtain aurantio-obtusin with yield and purity measurements under chromatographic conditions: column size (4.6 mm. times.250 mm, 5 μm), column temperature of column: the mobile phase of the chromatograph is methanol and 0.12 percent phosphoric acid solution at 36 ℃, the flow rate is controlled to be 1.1ml/min, and the detection wavelength is 255 nm. The results are shown in Table 1.
TABLE 1
The invention carries out auxiliary treatment on the alcohol solution of the cassia seed coarse powder by microwave, then carries out heating reflux, utilizes silica gel column and recrystallization to separate and purify the aurantio-obtusin, and obviously improves the yield and the purity of the aurantio-obtusin by optimizing the parameters of the particle size of the cassia seed coarse powder, the concentration and the dosage of the alcohol solution, the microwave condition, the composition of an eluant and the like.
Meanwhile, the preparation method is simple, has low requirements on equipment, short preparation time and low production cost, and simultaneously has small reagent dosage and is beneficial to environmental protection.
Experimental example evaluation of Bianduo stool function
See the defecation function test method specified in the "test and evaluation of health food" (2003 edition).
1. Preparation of test article
15g of each of the laxative health products prepared in examples 1-3 and comparative examples 1-3 was taken, 10 times of water was added, the mixture was soaked at 85 ℃ for 30min, filtered by gauze, repeatedly soaked for 2 times, 3 times of filtrates were combined, and concentrated in a water bath to 30ml, which is equivalent to 0.5g crude drug/ml.
2. Laboratory animal
Clean grade ICR mice, male, weighing 18-22 g.
3. Experimental methods
ICR mice are randomly divided into 8 groups, 10 mice are per group, and defecation experiments are carried out, wherein test groups 1-3 are respectively subjected to intragastric administration of the test substances of the defecation health-care products prepared in examples 1-3, comparison groups 1-3 are respectively subjected to intragastric administration of the test substances of the defecation health-care products prepared in comparative examples 1-3, the administration amount is 10 times (18.5g/kgd) of the recommended dose of a human body, a negative control group and a model control group are respectively subjected to intragastric administration of distilled water with the same volume, and continuous administration is carried out for 7 days. After 7 days of administration, mice in each group are fasted for 16 hours without water prohibition, and a model control group, experimental groups 1-3 and comparison groups 1-3 are respectively gavaged with compound diphenoxylate (10mg/Kg bw), and a negative control group is gavaged with distilled water with the same volume as the stomach.
After 0.5h of administration of the compound diphenoxylate, the mice of the negative control group and the model control group are subjected to intragastric gavage by ink, the test objects containing the ink are respectively intragastric-gavage of the experimental group 1-3 and the comparative group 1-3, timing is started after intragastric-gavage, the mice are placed in a metabolism cage, normal diet is recovered, the black defecation time of the first grain of each mouse, the number of the defecation grains within 6h and the total weight of the excrement are observed and recorded. The results are shown in Table 2.
TABLE 2
Group of | First granule defecation time/min | Number of black-discharged excrement particles/particle | Total weight of black excrement/g |
Model control group | 261.3±52.6** | 11±2.6** | 0.3745±0.1246* |
Negative control group | 176.4±19.2 | 20±3.2 | 0.5123±0.1210 |
Example 1 | 193.4±18.4# | 18±3.1# | 0.4779±0.1227# |
Example 2 | 197.1±17.1# | 17±2.9# | 0.4712±0.1231# |
Example 3 | 182.2±16.3# | 19±2.7# | 0.4926±0.1188# |
Comparative example 1 | 243.6±43.6 | 14±3.1 | 0.3935±0.1144 |
Comparative example 2 | 248.7±44.7 | 13±3.0 | 0.4015±0.1186 |
Comparative example 3 | 251.8±46.2 | 12±3.4 | 0.3884±0.1120 |
Note: compared with a negative control group, P is less than 0.01, and the difference is very significant; compared with the model control group, # P < 0.05, it is significantly different.
As can be seen from the table above, compared with the model control group, the first grain black stool discharging time, the number of grains discharging the stools within 6 hours and the total weight of the stools of the mice of the implementing groups 1 to 3 are significantly different (P is less than 0.05), which indicates that the health-care product for relaxing bowels prepared by the invention has good defecation effect.
Meanwhile, compared with a model control group, the first grain defecation time, the number of grains in defecation within 6h and the total weight of excrement of the mice in the control group 1-2 have no significant difference, and the preparation method of the aurantio-obtusin has an important influence on the defecation effect of the defecation health-care product claimed by the invention.
Compared with the prior art, the laxative health-care product disclosed by the invention has the advantages that the consumption of the senna leaves and the cassia seeds is obviously reduced by compounding the orange cassia tora essence with the senna leaves, the poria cocos, the radix glehniae, the Chinese yam and the like, the effect of relaxing bowel is obvious, and the safety is higher.
The above detailed description is specific to one possible embodiment of the present invention, and the embodiment is not intended to limit the scope of the present invention, and all equivalent implementations or modifications without departing from the scope of the present invention should be included in the technical scope of the present invention.
Claims (4)
1. A health product for relaxing bowels is characterized by comprising the following components in parts by weight: 10-15 parts of senna leaves, 8-15 parts of semen cassiae, 5-15 parts of black tea, 5-15 parts of green tea, 3-12 parts of poria cocos, 3-12 parts of radix glehniae, 20-30 parts of Chinese yam and 5-10 parts of honey, wherein the semen cassiae is prepared by adopting the following preparation method to obtain orange-yellow cassia seed essence;
the preparation method of the aurantio-obtusin comprises the following steps:
(1) mixing the coarse powder of the cassia seeds with a solvent, and performing microwave-assisted treatment to obtain a pretreatment solution;
(2) heating, refluxing, cooling and filtering the pretreatment liquid obtained in the step (1) to obtain a mixed liquid;
(3) carrying out silica gel column chromatography on the mixed solution obtained in the step (2), eluting, and collecting eluent;
(4) concentrating the eluent obtained in the step (3), and recrystallizing to obtain the aurantio-obtusin;
the particle size of the cassia seed coarse powder in the step (1) is 0.05-0.25 mm;
in the step (1), the solvent is ethanol water solution and n-butanol with the volume ratio of 8-10: 1;
the microwave auxiliary treatment in the step (1) comprises the following steps: the microwave power is 300-400W, and the microwave time is 20-40 s.
2. The laxative health product of claim 1, wherein the mass ratio of the cassia seed coarse powder to the solvent in the step (1) is 1: 10-15.
3. The laxative health product of claim 1, wherein the heating reflux in step (2) is: reflux extracting at 60-70 deg.C for 15-30 min.
4. The laxative health product of claim 1, wherein the eluent is a mixture of petroleum ether and acetone.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110521022.2A CN113214070B (en) | 2021-05-13 | 2021-05-13 | Preparation method of aurantio-obtusin and application of aurantio-obtusin in health-care product for relaxing bowels |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110521022.2A CN113214070B (en) | 2021-05-13 | 2021-05-13 | Preparation method of aurantio-obtusin and application of aurantio-obtusin in health-care product for relaxing bowels |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113214070A CN113214070A (en) | 2021-08-06 |
CN113214070B true CN113214070B (en) | 2022-03-11 |
Family
ID=77095612
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110521022.2A Active CN113214070B (en) | 2021-05-13 | 2021-05-13 | Preparation method of aurantio-obtusin and application of aurantio-obtusin in health-care product for relaxing bowels |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113214070B (en) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101967090A (en) * | 2010-06-28 | 2011-02-09 | 南京泽朗农业发展有限公司 | Technology for extracting aurantio-obtusin |
CN102283888B (en) * | 2011-07-27 | 2013-07-10 | 乔德亮 | Method for ultrasonic-assisted extraction of total flavones in cassia seed serving as Chinese medicine |
CN102924620B (en) * | 2012-11-13 | 2015-01-21 | 皖西学院 | Microwave-assisted method for extracting semen cassiae polysaccharide |
CN104998018A (en) * | 2015-06-28 | 2015-10-28 | 梅顺 | Foot bath powder conditioning constipation and production method thereof |
CN107361173A (en) * | 2017-03-21 | 2017-11-21 | 北京澳特舒尔保健品开发有限公司 | A kind of pure draft relaxes bowel tea bag health food and preparation method thereof |
-
2021
- 2021-05-13 CN CN202110521022.2A patent/CN113214070B/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN113214070A (en) | 2021-08-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1066055C (en) | Production method for extracting flavonoid compound extract or powder from bamboo leaf | |
CN102633895B (en) | Extraction and preparation method by comprehensively utilizing liquorice | |
CN104059121B (en) | A kind of method preparing cucurbitacin, dihydrocucurbitacin F | |
CN102697047B (en) | Method for preparing oral liquid of Chinese wolfberry | |
CN102443072A (en) | Method for simultaneously extracting polysaccharides and saponins from astragalus | |
CN112870236B (en) | Flavone effective part of abelmoschus manihot and preparation method and application thereof | |
CN102302560A (en) | Composition of lucid ganoderma extract and tartary buckwheat extract, as well as application thereof | |
CN101612243A (en) | A kind of application process of natural plant pepper extract | |
CN111057163A (en) | Preparation method and application of inonotus obliquus extract | |
CN102068535B (en) | Immature bitter orange or bitter orange total flavonoids extract prepared by ethanol reflux and extraction and application thereof | |
CN103480178A (en) | Method for extracting active ingredients from coreopsis tinctoria by subcritical water | |
CN112294830B (en) | American ginseng leaf product rich in rare ginsenoside | |
CN104127451A (en) | Method of simultaneously extracting polyphenol, flavonoids and triterpenes from pomegranate flowers | |
CN102091122B (en) | Compound hypotensive Chinese medicinal preparation and preparation method thereof | |
CN113214070B (en) | Preparation method of aurantio-obtusin and application of aurantio-obtusin in health-care product for relaxing bowels | |
CN105816597B (en) | A kind of Chinese medicine pre-mixing agent and preparation method thereof for preventing and treating prevention of sow constipation | |
CN106749487A (en) | A kind of method that separating ursolic acid is extracted from seabuckthorn fruit peel | |
CN103655791A (en) | Lotus leaf-based preparation for treating phlegm and blood stasis simultaneously and application thereof | |
CN103800418B (en) | Composition for promoting blood circulation and stopping pain, capsule preparation technology and application thereof | |
CN104262448B (en) | Method for extracting glycyrrhizic acid for licorice | |
CN112121071B (en) | A product prepared from Ginseng radix | |
CN107114514A (en) | A kind of heat-clearing Antilipemic slimming tea and preparation method thereof | |
CN113827660A (en) | Traditional Chinese medicine composition for reducing blood sugar and blood fat and preparation method thereof | |
CN108096330B (en) | Method for extracting and purifying total anthraquinone in rheum officinale | |
CN106074630A (en) | A kind of Flavones from Ginkgo Leaves extracting method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |